Article Text

Download PDFPDF
Author’s reply
  1. S D Aaron
  1. Dr S D Aaron, The Ottawa Hospital/Ottawa Health Research Institute, General Campus 501, Smyth Road Mailbox #211, Ottawa, Canada K1H 8L6; saaron{at}ohri.ca

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We would like to thank Dr Vestbo for his comments. We agree that in the Optimal Trial more patients originally randomised to the placebo arm prematurely discontinued study medications, and that many of these patients were subsequently put on open label ICS/LABA products.1 As discussed in our paper, the relative risk reduction decreased from 21% if patients were prematurely excluded once they discontinued study drugs to 15% when an intent to treat analysis was used.2 We agree with Dr Vestbo that our intention …

View Full Text

Footnotes

  • Competing interests: None.